×
About 66,368 results

Robotic Surgery Proves Its Mettle for Liver Cancer
https://www.medpagetoday.com/surgery/generalsurgery/101923

Nov 23rd, 2022 - Fully robotic liver resection was safe and effective for patients with hepatocellular carcinoma (HCC) compared with open liver resection, a cohort study found. Propensity score-matched analysis showed "better perioperative tolerability ... based on clinical, oncologic, and technical criteria" compared with open resection, reported Fabrizio Di Benedetto, MD, PhD, of the University of Modena and ...

Vax Conspiracy Film Hits Twitter; More Apnea Device Deaths; GSK Pulls Cancer Drug
https://www.medpagetoday.com/infectiousdisease/covid19vaccine/101895

Nov 23rd, 2022 - Note that some links may require subscriptions. Also note that Morning Break will be taking its own break Thursday and Friday for the Thanksgiving holiday. Look for it again on Monday, November 28. The anti-vax film "Died Suddenly," which claims COVID vaccines were designed to depopulate the world, premiered on Twitter. (Forbes) Pediatric hospitalizations spiked up to 60% on Long Island as resp...

Rhinitis Patients Report Symptomatic Medication Use in Mobile App
https://www.medscape.com/viewarticle/984571

Nov 23rd, 2022 - Patients with rhinitis treat their condition as symptoms arise, rather than by guidelines on how to keep their disease under control, suggests a longitudinal study that confirms cross-sectional analyses. Investigators captured data from patients in 25 countries via a mobile application called MASK-air. The app provides real-world data on patient experiences with their allergic rhinitis and how ...

Cancer Prevention and Treatment in Europe vs. the U.S.
https://www.medscape.com/viewarticle/984307

Nov 23rd, 2022 - JOHN WHYTE: Welcome, everyone. I'm Dr. John Whyte, the Chief Medical Officer of WebMD. And you're watching our video series, Cancer in Context, where we explore some of the latest innovations in cancer care. Have you ever wondered about cancer rates around the world? Here in the United States, we have higher cancer rates than Europe. But also higher survival rates. Does treatment vary based on ...

FDA approves CSL's gene therapy for hemophilia
https://www.reuters.com/article/uniqure-fda/fda-approves-csls-gene-therapy-for-hemophilia-idUSL4N32I3G6

Nov 22nd, 2022 - Nov 22 (Reuters) - The U.S. health regulator on Tuesday approved Australian drugmaker CSL Ltd and partner Uniqure NV’s gene therapy for hemophilia B, potentially offering a long-term solution for patients with the blood clotting disorder. The approval from the Food and Drug Administration makes the treatment, which will be branded Hemgenix, the first gene therapy for the rare inherited disorder...

US STOCKS-Retailer, energy boost helps Wall Street rally
https://www.reuters.com/article/usa-stocks/us-stocks-retailer-energy-boost-helps-wall-street-rally-idUSL1N32I26F

Nov 22nd, 2022 - (For a Reuters live blog on U.S., UK and European stock markets, click or type LIVE/ in a news window.) Best Buy up, sees smaller annual sales drop Dollar Tree drops on lower FY profit forecast Manchester United surges on sale report (Updates to market close) NEW YORK, Nov 22 (Reuters) - U.S. stocks rallied on Tuesday in light trading volume as a sales forecast by Best Buy dampened concerns hig...

Updated COVID vaccines offer better protection than original -U.S. study
https://www.reuters.com/article/health-coronavirus-booster-study/updated-covid-vaccines-offer-better-protection-than-original-u-s-study-idUSL1N32I1WB

Nov 22nd, 2022 - Nov 22 (Reuters) - Updated COVID-19 boosters offer increased protection against new variants in people who have previously received up to four doses of the older vaccine, a real-world study in the United States showed. The study of over 360,000 people, published in Morbidity and Mortality Weekly Report, offers the first evidence that the new vaccines by Pfizer-BioNTech and Moderna provide bette...

Anti-Vax Verified on Twitter; 'Laughing Gas' on the Rise; Medicare Advantage Errors
https://www.medpagetoday.com/infectiousdisease/covid19/101862

Nov 22nd, 2022 - Note that some links may require subscriptions. When it comes to vaccines, "verified" anti-vax accounts are proliferating on Twitter as the platform's content and curation controls shift in the wake of its recent ownership transition. (The Guardian) As this year's holiday (and respiratory virus) season heats up, this is how a bevy of infectious disease experts are currently responding to COVID,...

Women Need Not Wait to Conceive After Miscarriage, Abortion
https://www.medscape.com/viewarticle/984508

Nov 22nd, 2022 - Women who conceived within 6 months of having a miscarriage or an induced abortion did not appear to be at an increased risk of a problematic pregnancy, a new study of more than 70,000 live births in Norway has found. The findings, published online today in PLOS Medicine, should help women and clinicians navigate conflicting guidance over how soon it is safe to conceive again after a pregnancy ...

ACR, EULAR Roll Out Updated Antiphospholipid Syndrome Criteria
https://www.medscape.com/viewarticle/984452

Nov 22nd, 2022 - PHILADELPHIA — A draft update of criteria for classifying antiphospholipid syndrome (APS) incorporates a much broader spectrum of disease signs and symptoms, such as kidney disease and more variables for pregnancy, and meets a higher level of specificity than the existing Sapporo criteria, although at the expense of lower sensitivity. Members of the ACR/EULAR core planning group, (left to right...

Berlin Zoo Unexpectedly Closes After Bird Flu Case
https://www.medscape.com/viewarticle/984308

Nov 21st, 2022 - BERLIN (Reuters) - Berlin's zoo closed its doors without warning on Friday out of precaution after a case of avian flu was discovered in a wading bird that died earlier this week, it said in a statement. The zoo, which welcomed over 3.7 million guests in 2019, its latest figure, did not mention when it would reopen to visitors. "We have reacted immediately with far-reaching quarantine measures....

Vaccines and Drugs in the Pipeline for RSV
https://www.medscape.com/viewarticle/984330

Nov 21st, 2022 - (Reuters) - There are no approved vaccines and only one drug in the United States for respiratory syncytial virus (RSV), a common respiratory virus that usually causes mild, cold-like symptoms but can also lead to serious illness and hospitalization. Sanofi SA and AstraZeneca Plc's drug nirsevimab recently became the second to get Europe's approval to prevent RSV infections in infants, after Sw...

Dermatologists Predict That Skin Cancer Cases Will Double
https://www.medscape.com/viewarticle/984407

Nov 21st, 2022 - The number of skin cancer cases in men and women increases by 10% every year. Experts have drawn a correlation between this increase and the increased intensity of UV radiation in Germany. Skin cancer is already one of the most common forms of cancer. In Germany, around 260,000 people develop skin cancer each year, regardless of whether they have light or dark skin. It became clear at the press...

Peru Reports First Severe Bird Flu Outbreak
https://www.medscape.com/viewarticle/984292

Nov 21st, 2022 - PARIS (Reuters) - Peru has reported its first outbreak of highly pathogenic avian influenza as the disease swept through some wild pelicans, the Paris-based World Organisation for Animal Health (WOAH) said on Friday. The type A H5 virus killed 200 pelicans that were found on a beach in the northern province of Paita, WOAH said, citing a report from the Peruvian authorities. Commonly called bird...

EMA Recommends Limiting the Indications for JAK Inhibitors
https://www.medscape.com/viewarticle/984399

Nov 21st, 2022 - AMSTERDAM — In an effort to minimize the risk of serious side effects associated with Janus kinase (JAK) inhibitors, the Pharmacovigilance Risk Assessment Committee (PRAC) of the European Medicines Agency (EMA) has recommended limiting the indications for which these medicines are used — namely chronic inflammatory disorders, such as rheumatoid arthritis, psoriatic arthritis, juvenile idiopathi...

Banned Blood Donors Welcomed Again as Mad Cow Disease Concerns Fade
https://www.medscape.com/viewarticle/984414

Nov 21st, 2022 - Organizations like the American Red Cross and others are stepping up efforts to recruit previously banned blood donors after the FDA lifted its restrictions on people who had been overseas amid outbreaks of mad cow disease. "This eligibility change will potentially impact hundreds of thousands of individuals who were previously ineligible to give blood or platelets, including many in the milita...

Advanced Prostate Cancer Treatment Benefits From Updated Guidelines and Adaptive Sequencing Strategies
https://www.onclive.com/view/advanced-prostate-cancer-treatment-benefits-from-updated-guidelines-and-adaptive-sequencing-strategies

Nov 18th, 2022 - Treatment developments in advanced prostate cancer are hinging on the benefits of triplet therapy and individualized care, the results of which are also informing treatment sequencing, according to Jason M. Hafron, MD. In an interview during the 2022 LUGPA Annual Meeting, Hafron shared advice on optimizing advanced prostate cancer clinics, recapped the biggest advances in urologic cancer trea...

European Commission Approves Zanubrutinib for CLL
https://www.onclive.com/view/european-commission-approves-zanubrutinib-for-cll

Nov 18th, 2022 - The European Commission has approved zanubrutinib (Brukinsa) for the treatment of adult patients with treatment-naïve or relapsed/refractory chronic lymphocytic leukemia (CLL).1 The approval is based on positive findings from the phase 3 SEQUOIA (NCT03336333) and ALPINE (NCT03734016) trials in patients with previously untreated and relapsed/refractory CLL, respectively. In both trials, zanubru...

FDA Seeks to Restrict Rucaparib to Second-line Maintenance Therapy in Recurrent Ovarian Cancer
https://www.onclive.com/view/fda-seeks-to-restrict-rucaparib-to-second-line-maintenance-therapy-in-recurrent-ovarian-cancer

Nov 18th, 2022 - The FDA has asked Clovis Oncology to limit use of rucaparib (Rubraca) to second-line maintenance therapy for patients with recurrent ovarian cancer harboring BRCA mutations.1 The company is considering the FDA’s request. If the 2 sides cannot reach an agreement on the revised indication, the FDA said would convene an Oncologic Drugs Committee meeting to review the matter. Clovis warned investo...

BTK Inhibitor Failure Signals Unmet Need for a Standard of Care in Relapsed/Refractory MCL
https://www.onclive.com/view/btk-inhibitor-failure-signals-unmet-need-for-a-standard-of-care-in-relapsed-refractory-mcl

Nov 18th, 2022 - Improved mantle cell lymphoma (MCL) treatments are necessary for patients who have relapsed on or are refractory to BTK inhibitors, according to findings from SCHOLAR-2, a multicenter, retrospective chart review of European patients with MCL who relapsed following or were intolerant to BTK inhibitors. In the overall patient cohort (n = 240), the median overall survival (OS) from the initiati...